<?xml version="1.0" encoding="UTF-8"?>
<p>It is vitally important that pregnant women be considered in the design, clinical trial, and implementation of vaccine candidates for 2019-nCoV. In examining the history of vaccine design, it is clear that the needs of pregnant women have rarely been prioritized in either the preclinical development or the clinical trial phases of production. Today, pregnant women are usually excluded from experimental trial of drugs and vaccines that do not target obstetric conditions [
 <xref rid="B69-viruses-12-00194" ref-type="bibr">69</xref>]. Excluding pregnant women and their infants from participation in vaccine development and implementation undermines ethical principles of justice—fairness, equity, and maximization of benefit—and potentially places their health at risk during outbreaks and other health emergencies [
 <xref rid="B69-viruses-12-00194" ref-type="bibr">69</xref>,
 <xref rid="B70-viruses-12-00194" ref-type="bibr">70</xref>,
 <xref rid="B71-viruses-12-00194" ref-type="bibr">71</xref>].
</p>
